Lakefront Biotherapeutics (GLPGF) Change in Receivables (2015 - 2020)

Lakefront Biotherapeutics (GLPGF) has reported Change in Receivables for 6 consecutive years, with -$51.4 million the latest figure, recorded in Q2 2020.

• On a quarterly basis, Change in Receivables fell 233.93% year-over-year to -$51.4 million in Q2 2020; TTM through Jun 2020 was $16.8 million, a 49.56% decrease from a year earlier, with the FY2025 full-year figure at $97.8 million, up 391.05% from the prior year.
• Change in Receivables was -$51.4 million for Q2 2020 at Lakefront Biotherapeutics, down from $30.4 million in the prior quarter.
• Over five years, Change in Receivables peaked at $2.6 billion in Q3 2017 and troughed at -$2.5 billion in Q2 2017.
• A 5-year average of $10.3 million and a median of -$5.7 million in 2016 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables tumbled 44027.92% in 2017 and soared 2626.81% in 2019, its largest moves.
• Over 5 years, Change in Receivables stood at -$14.0 million in 2016, then advanced by 2.65% to -$13.6 million in 2017, then soared by 128.39% to $3.9 million in 2018, then soared by 2626.81% to $105.6 million in 2019, then sank by 148.64% to -$51.4 million in 2020.
• The last three Change in Receivables figures came in at -$51.4 million (Q2 2020), $30.4 million (Q1 2020), and $105.6 million (Q4 2019), per Business Quant data.